FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study

por Douglas, Raymond, Ugradar, Shoaib, Cockerham, Kimberley, Eric Turbin, Roger, Tang, Rosa, Nijhawan, Navdeep, O’Shaughnessy, Denis J, Summerfelt, Rochelle M, She, Angela, Katz, Barrett
Publicado 2023